AML: relapse within 3 months of transplant portends poor survival

  • de Jong G & al.
  • Eur J Haematol
  • 14 Aug 2019

  • curated by David Reilly
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with acute myeloid leukemia (AML) who relapse

Why this matters

  • Relapse after allo-HSCT accounts for 30%-40% of posttransplant deaths.

Study design

  • Analysis of outcomes in 83 patients with AML who experienced relapse after allo-HSCT.
  • All patients studied had undergone transplantation between 2010 and 2016 and experienced relapse before the end of 2017.
  • 80 patients had AML; 3 had chronic myelomonocytic leukemia or high-risk myelodysplastic syndromes.
  • Patients were stratified by intention to treat: curative (CIT; n=50) vs best supportive care (BSC; n=33).
  • Median age at time of allo-HSCT: 54 (interquartile range, 47-62) years.
  • Funding: None disclosed.

Key results

  • 44% in the CIT group achieved complete remission (CR) with reinduction chemotherapy; one-half of these patients survived through observation.
  • 69% of survivors had received high-intensity cytarabine treatment and subsequent immunologic consolidation.
  • Relapse at
  • >50% experienced relapse at

Limitations

  • Retrospective data.